| 0.9864 -0.184 (-15.69%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.66  |
1-year : | 1.98 |
| Resists | First : | 1.42 |
Second : | 1.7 |
| Pivot price | 1.33 |
|||
| Supports | First : | 0.97 |
Second : | 0.81 |
| MAs | MA(5) : | 1.26 |
MA(20) : | 1.35 |
| MA(100) : | 2.27 |
MA(250) : | 3.21 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 26.7 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 10 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNTA ] has closed below the lower bollinger band by 22.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GNTA ] is to continue within current trading range. It is unclear right now based on current values. 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.17 |
| Low: | 0.96 - 0.97 | 0.97 - 0.98 |
| Close: | 0.97 - 0.99 | 0.99 - 1 |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Tue, 27 Jan 2026
Genenta Science Stock Surges Amid Strategic Expansion Moves - timothysykes.com
Tue, 27 Jan 2026
GNTA’s New Partnership Sparks Investor Interest and Stock Surge - StocksToTrade
Tue, 27 Jan 2026
Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments - Benzinga
Tue, 27 Jan 2026
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Tue, 27 Jan 2026
GNTA Stock Sees Wild Fluctuations Amid Market Shifts - timothysykes.com
Tue, 27 Jan 2026
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 37.4 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 78 (K) |
| Shares Short P.Month | 168 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -60.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|